Limited Time Offer

Claim a 25% discount on your eLearning and instructor-led courses purchases with code EDU25OFF.

Offer is valid from October 1-31. Exclusions may apply.

Probing Metabolic Changes in Cancer with Raman Spectroscopy in Response to Treatment, and Validated with Mass Spectrometry

Source: AIChE
  • Type:
    Conference Presentation
  • Checkout

    Checkout

    Do you already own this?

    Pricing


    Individuals

    AIChE Member Credits 0.5
    AIChE Members $19.00
    AIChE Graduate Student Members Free
    AIChE Undergraduate Student Members Free
    Non-Members $29.00
  • Conference Type:
    AIChE Annual Meeting
  • Presentation Date:
    November 16, 2020
  • Duration:
    15 minutes
  • Skill Level:
    Intermediate
  • PDHs:
    0.30

Share This Post:

Rapid and accurate response to targeted therapies is critical to differentiate tumors that are resistant to treatment early in the regimen. In this talk, I will demonstrate a recent work by my group where we show a rapid, noninvasive, and label-free approach to evaluate metabolic changes in breast cancer (BC) cells with Raman spectroscopy (RS) in response to treatment with molecular inhibitors. We applied multivariate analysis to RS data to classify the cells into responsive or nonresponsive groups as a function of drug dosage, drug type, and cell type. Metabolites identified with RS were then validated with mass spectrometry (MS), a gold standard in metabolism. We treated triple-negative BC cells with Trametinib, an inhibitor of the extracellular-signal-regulated kinase (ERK) pathway. Changes measured with both RS and MS corresponding to membrane phospholipids, amino acids, lipids and fatty acids indicated that these BC cells were responsive to treatment. Comparatively, minimal metabolic changes were observed post-treatment with Alpelisib, an inhibitor of the mammalian target of rapamycin (mTOR) pathway, indicating treatment resistance. These findings were corroborated with cell viability assay and immunoblotting. We also showed estrogen receptor-positive MCF-7 cells were nonresponsive to Trametinib with minimal metabolic and viability changes. Our findings support that oncometabolites identified with RS will ultimately enable rapid drug screening ensuring patients receive the most effective treatment at the earliest time point.
Presenter(s): 
Once the content has been viewed and you have attested to it, you will be able to download and print a certificate for PDH credits. If you have already viewed this content, please click here to login.

Checkout

Checkout

Do you already own this?

Pricing


Individuals

AIChE Member Credits 0.5
AIChE Members $19.00
AIChE Graduate Student Members Free
AIChE Undergraduate Student Members Free
Non-Members $29.00
Language: